Oneness Biotech Co., Ltd.
Taipei Exchange 4743.TWO
Oneness Biotech Co., Ltd. Free Cash Flow Yield on January 14, 2025: -1.46%
-
Oneness Biotech Co., Ltd. 52-week high Free Cash Flow Yield is -0.63% on March 07, 2024, which is 56.98% above the current Free Cash Flow Yield.
-
Oneness Biotech Co., Ltd. 52-week low Free Cash Flow Yield is -1.51% on January 13, 2025, which is -3.15% below the current Free Cash Flow Yield.
-
Oneness Biotech Co., Ltd. average Free Cash Flow Yield for the last 52 weeks is -0.82%.
| Date | Free Cash Flow Yield | Market Value Added (MVA) | Price to Book Ratio (P/B) | Price to Earnings Ratio (P/E) |
|---|
| CEO | Mr. Nien-Yi Chen |
| IPO Date | Sept. 23, 2011 |
| Location | Taiwan |
| Headquarters | No.236, Xinyi Road |
| Employees | 180 |
| Sector | Health Care |
| Industries | |
Oneness Biotech Co., Ltd engages in the research and development of new drugs, and sale of pharmaceutical and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis and systemic sclerosis; FB825, which is in Phase II clinical trial for treating atopic dermatitis, allergic diseases, and asthma; and FB918, a human monoclonal antibody, which is in pre-clinical stage for the treatment of allergic asthma. In addition, the company engages in the management of agriculture cultivation and trading business; and sale of agricultural products. The company was incorporated in 2008 and is headquartered in Taipei City, Taiwan.
Past 5 years
USD 1.53
USD 1.70
USD 0.93
StockViz Staff
January 15, 2025
Any question? Send us an email